Beijing Konruns Pharmaceutical (603590.SH) issued a profit warning, expecting a net profit of 40 to 55 million yuan in 2024, a decrease of 63% to 73% year-on-year.

Beijing Konruns Pharmaceutical (603590.SH) announced that the company expects to achieve a net profit attributable to owners of the parent company of 40 to 55 million yuan in 2024. Compared with the same period last year (disclosed statutory data), it will decrease by 95.45 million to 110.45 million yuan, a year-on-year decrease of 63% to 73%.